Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ezetimibe
Drug ID BADD_D00864
Description Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating the effect of ezetimibe on intestinal cholesterol absorption.[A15202] Ezetimibe is used as an adjunctive therapy to a healthy diet to lower cholesterol levels in primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia (phytosterolemia).[L11347] Unlike other classes of cholesterol-reducing compounds including statins and bile acid sequestrants, ezetimibe has a distinct mechanism of action involving the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1), and is unique in that it does not affect the absorption of fat-soluble nutrients such as fat-soluble vitamins, triglycerides, or bile acids.[A33313] In genetically NPC1L1-deficient mice, a 70% reduction in intestinal cholesterol absorption was seen, and these mice were insensitive to ezetimibe treatment - it was determined based on these findings that NPC1L1 plays an essential role in promoting intestinal cholesterol uptake via an ezetimibe-sensitive pathway.[A15202] By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces the delivery of intestinal cholesterol to the liver.[L11347]
Indications and Usage For use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
Marketing Status Prescription
ATC Code C10AX09
DrugBank ID DB00973
KEGG ID D01966
MeSH ID D000069438
PubChem ID 150311
TTD Drug ID D09LWS
NDC Product Code 60429-982; 72189-118; 63629-7413; 66039-839; 0591-3713; 70966-0027; 70518-2262; 0781-5690; 65096-0113; 69218-0400; 55111-079; 71205-277; 51660-200; 50228-379; 66039-896; 78206-178; 65015-812; 50268-298; 68382-773; 59651-052; 71335-1354; 50090-3657; 71335-0933; 71205-145; 16729-433; 75895-0281; 70518-3334; 58032-2004; 71335-1127; 50090-3087; 69218-0800; 15894-0011; 70771-1109; 66039-869; 68554-0085; 16714-813; 59651-056; 60687-373; 0615-8300; 0904-6664; 71335-0684; 64176-0042; 69238-1154; 0904-7103; 60505-2945; 14501-0008; 67877-490
Synonyms Ezetimibe | (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone) | Ezetimib | Ezetrol | SCH 58235 | 58235, SCH | SCH-58235 | SCH58235 | Zetia
Chemical Information
Molecular Formula C24H21F2NO3
CAS Registry Number 163222-33-1
SMILES C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cognitive disorder19.21.02.001; 17.03.03.003--
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.000123%Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.0040.000471%
Hepatic enzyme increased13.03.01.0190.000942%Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Brain neoplasm16.30.01.003; 17.20.01.0030.000082%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.0030.000164%Not Available
Connective tissue disorder15.06.01.006--Not Available
Infestation23.09.05.001; 11.09.01.001--Not Available
Inflammation08.01.05.007--Not Available
Limb discomfort15.03.04.0140.000314%Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.0010.000471%
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Autoimmune disorder10.04.04.0030.000628%
Drug intolerance08.06.01.0130.002670%Not Available
Pancreatic neoplasm16.13.11.005; 07.21.09.0040.000471%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.0100.000628%Not Available
Peripheral arterial occlusive disease24.04.03.0100.000314%Not Available
Hepatic enzyme abnormal13.03.01.020--Not Available
Spontaneous haematoma24.07.01.054; 01.01.03.0060.000471%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.000471%
Immune-mediated necrotising myopathy15.05.05.008; 10.04.05.0060.003299%Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages